+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Computer-Aided Drug Discovery - Global Strategic Business Report

  • PDF Icon

    Report

  • 375 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5997973
The global market for Computer-Aided Drug Discovery was estimated at US$3.6 Billion in 2023 and is projected to reach US$7.1 Billion by 2030, growing at a CAGR of 9.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

How Does Computer-Aided Drug Discovery Work and What Are Its Core Technologies?

Computer-aided drug discovery (CADD) is a cutting-edge approach that leverages computational methods to accelerate and refine the drug discovery process, traditionally a time-consuming and costly endeavor. At its core, CADD involves the use of sophisticated algorithms and simulations to model the interactions between potential drug candidates and biological targets, such as proteins or enzymes. The process begins with the identification of a target, followed by the screening of vast libraries of chemical compounds, which are analyzed for their potential to bind effectively with the target and modulate its activity. Technologies such as molecular docking, molecular dynamics simulations, and quantitative structure-activity relationship (QSAR) modeling play pivotal roles in this process. Molecular docking, for instance, predicts how a drug molecule will fit into a target site, while molecular dynamics simulations provide insights into the stability and behavior of the drug-target complex over time. QSAR modeling helps in predicting the biological activity of compounds based on their chemical structure. These computational tools not only streamline the early stages of drug discovery but also allow for the optimization of lead compounds by predicting their pharmacokinetic and toxicity profiles, ultimately leading to more effective and safer drugs.

Who Benefits from Computer-Aided Drug Discovery and How Is It Transforming Pharmaceutical Research?

The benefits of computer-aided drug discovery extend across the pharmaceutical industry, academic research institutions, and ultimately, patients who stand to gain from faster access to new and effective treatments. Pharmaceutical companies, faced with the immense financial and time pressures of bringing new drugs to market, benefit significantly from the efficiency gains offered by CADD. By reducing the need for extensive laboratory experimentation and enabling the rapid screening of millions of compounds, CADD accelerates the identification of promising drug candidates, reducing both the time and cost associated with drug development. Academic researchers also leverage CADD to explore novel therapeutic targets and mechanisms of action, often leading to the discovery of innovative drugs for conditions that have been challenging to treat with conventional methods. For patients, the impact of CADD is seen in the form of more targeted therapies with fewer side effects, as the precision of computational modeling allows for the design of drugs that are tailored to interact specifically with disease-causing molecules while minimizing interactions with healthy cells. As a result, computer-aided drug discovery is not only transforming the pharmaceutical landscape but also paving the way for more personalized and effective healthcare.

What Are the Latest Innovations and Trends in Computer-Aided Drug Discovery?

The field of computer-aided drug discovery is rapidly evolving, with several emerging trends and innovations shaping the future of pharmaceutical research. One of the most significant developments is the integration of artificial intelligence (AI) and machine learning (ML) into the CADD process. AI-driven algorithms are capable of analyzing vast datasets, identifying patterns, and predicting the activity of drug candidates with unprecedented accuracy. This has led to the emergence of AI-based drug discovery platforms that can autonomously generate novel compounds, optimize existing ones, and even predict clinical outcomes. Another trend is the increasing use of cloud computing and big data analytics, which allow researchers to harness the power of distributed computing to perform complex simulations and analyze large datasets more efficiently. The rise of quantum computing, though still in its early stages, holds the potential to revolutionize CADD by enabling the simulation of molecular interactions at an atomic level, leading to more accurate predictions of drug efficacy and safety. Additionally, the use of multi-omics data, including genomics, proteomics, and metabolomics, is becoming increasingly important in CADD, enabling a more comprehensive understanding of disease mechanisms and the identification of new drug targets. These innovations are pushing the boundaries of what is possible in drug discovery, leading to faster, more cost-effective, and more precise therapeutic development.

What Is Driving the Growth of the Computer-Aided Drug Discovery Market?

The growth in the computer-aided drug discovery market is driven by several factors that reflect the ongoing transformation of the pharmaceutical and biotechnology industries. One of the primary drivers is the increasing complexity of disease biology, which demands more sophisticated tools for drug discovery. As diseases like cancer, neurological disorders, and rare genetic conditions become better understood, there is a growing need for targeted therapies that can address these complex conditions effectively. Technological advancements, particularly in AI, machine learning, and quantum computing, are making CADD more powerful and accessible, further driving its adoption across the industry. The rising cost of drug development and the pressure to reduce time-to-market for new therapies are also significant factors, as CADD offers a solution that can streamline the drug discovery process and reduce the financial risks associated with it. Additionally, the growing focus on personalized medicine, which requires the development of therapies tailored to individual patients based on their genetic profiles, is fueling demand for CADD technologies that can design drugs with high specificity and efficacy. The increasing collaboration between pharmaceutical companies, academic institutions, and technology providers is also fostering innovation and expanding the capabilities of CADD. Together, these factors are propelling the growth of the computer-aided drug discovery market, positioning it as a key driver of future advancements in medicine.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Ligand-based Design segment, which is expected to reach US$3.2 Billion by 2030 with a CAGR of a 10.7%. The Structure-based Design segment is also set to grow at 9.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $993.9 Million in 2023, and China, forecasted to grow at an impressive 13.7% CAGR to reach $1.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Computer-Aided Drug Discovery Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Computer-Aided Drug Discovery Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Computer-Aided Drug Discovery Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Bayer AG, Charles River Laboratories International, Inc., ChemDiv, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 36 Featured):

  • Bayer AG
  • Charles River Laboratories International, Inc.
  • ChemDiv, Inc.
  • Pharmaron Beijing Co., Ltd.
  • BOC Sciences
  • Chemical Computing Group ULC
  • Curia Global, Inc.
  • Bioduro-Sundia
  • Aaranya Biosciences Pvt. Ltd.
  • Aris Pharmaceuticals, Inc

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Computer-Aided Drug Discovery - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Complexity of Disease Mechanisms Expands Addressable Market Opportunity for Advanced CADD Tools
  • Integration of Artificial Intelligence and Machine Learning Spurs Growth in Computer-Aided Drug Discovery Market
  • Advancements in High-Performance Computing Propel Adoption of Computer-Aided Drug Discovery Solutions
  • Increasing Use of Big Data Analytics in Drug Development Accelerates Demand for Computational Approaches
  • Emergence of Cloud-Based Solutions Expands Access to Computer-Aided Drug Discovery Resources
  • Rising Pressure to Reduce Drug Development Costs and Time-to-Market Sustains Growth in CADD Applications
  • Here's How Advances in Quantum Computing Are Poised to Revolutionize Computer-Aided Drug Discovery
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Computer-Aided Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Computer-Aided Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Ligand-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Ligand-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Ligand-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Structure-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Structure-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Structure-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Sequence-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Sequence-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Sequence-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Research Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 30: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: World 16-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 36: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
AUSTRALIA
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned

  • Bayer AG
  • Charles River Laboratories International, Inc.
  • ChemDiv, Inc.
  • Pharmaron Beijing Co., Ltd.
  • BOC Sciences
  • Chemical Computing Group ULC
  • Curia Global, Inc.
  • Bioduro-Sundia
  • Aaranya Biosciences Pvt. Ltd.
  • Aris Pharmaceuticals, Inc

Table Information